Israel’s Brainsway, which develops advanced technology solutions for the treatment of a variety of brain disorders, has opened an American subsidiary. The company declared that Brainsway USA will provide enhanced sales, marketing, customer support and logistics for Brainsway’s rapidly growing U.S. customer base.
The company said that it has made the move due to the increased interest in its technology and initiatives in the U.S., and in light of a heightened focus on the U.S. as Brainsway’s key strategic market.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
Brainsway boasted that the new U.S.-based entity has already recruited key personnel and is building a versatile team of experienced professionals, technicians, service providers, sales representatives and others. Brainsway USA assumed direct responsibility for sales, marketing, customer support and logistics for Brainsway’s U.S. customer base on January 1, 2015.
Also joining the new entity are a number of officials formerly of Nvation, including Dr. Walt Duffy, who will serve as Brainsway USA’s Clinical Advisor, and Matt Duffy, who will serve as its Customer Relations Director and Midwest Business Development Specialist. Brainsway and Nvation have mutually decided to terminate their non-exclusive U.S. distribution and logistics center agreements effective December 31, 2014. Brainsway USA is headquartered in the Northeast U.S. and has opened 2 additional regional service centers enabling complete coverage and maximum penetration of the U.S. market.
Brainsway Ltd. develops and markets Deep TMS (Deep Transcranial Magnetic Stimulation) systems, for treatment of brain disorders. The unique technology of Brainsway is based on patents filed by the National Institute of Health (NIH), and by the company. Brainsway has an exclusive license from the NIH for the patent and technology. Brainsway’s technology was cleared by the FDA for treatment of depression patients who did not respond to any number of medication treatments in the current depressive episode. Brainsway’s Deep TMS was enthusiastically received by the international academic community, with 60 clinical trials held in major institutions worldwide.
